Liposomal chemotherapy market seen growing to $4.87 billion by 2030

The Business Research Company says the liposomal chemotherapy market will expand from $3.11 billion in 2025 to $3.39 billion in 2026, then reach $4.87 billion by 2030. The report points to rising cancer rates, demand for targeted drug delivery and newer nanotechnology-based formulations as key growth drivers.

Why it matters: - Liposomal chemotherapy is designed to deliver cancer drugs more precisely, which can reduce toxicity and improve treatment effectiveness. - The market’s projected growth signals continued investment in cancer therapies that aim to limit side effects from traditional chemotherapy.

What happened: - The Business Research Company released its “Liposomal Chemotherapy Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035.” - The report says the market will rise from $3.11 billion in 2025 to $3.39 billion in 2026. - The report projects the market will reach $4.87 billion by 2030. - The company says the market will grow at a 9.2% CAGR from 2025 to 2026 and a 9.5% CAGR through 2030.

The details: - Liposomal chemotherapy encapsulates anticancer drugs inside liposomes, which are microscopic lipid-based vesicles. - The format is intended to increase drug concentration at tumor sites while reducing exposure to healthy tissue. - The approach is also designed to improve drug stability, extend circulation time in the bloodstream and boost therapeutic efficacy. - The report links recent market growth to the toxicity of standard chemotherapy, limited tumor targeting in conventional delivery methods, rising cancer incidence and stronger demand for cancer therapies. - The report also cites first-generation liposomal drug formulations and broader hospital-based chemotherapy infusions as contributors to expansion. - Future growth drivers include personalized oncology, precision medicine, toxicity-reducing chemotherapy systems, nanotechnology-driven drug delivery and more clinical trials for advanced liposomal formulations. - Biomarker-guided cancer therapies are expected to play a larger role during the forecast period. - Emerging trends include precision nanocarrier delivery systems, better drug accumulation in tumor microenvironments, long-circulating stealth liposome formulations, combination therapies and biomarker-guided personalization. - North America was the largest regional market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa. - The report offers market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, hotspot infographics, and updated graphics and tables. - The company offers a free sample report and a full report through the company’s announcement.

Between the lines: - The forecast suggests oncology developers and drug-delivery specialists are shifting toward platforms that can improve precision without increasing systemic toxicity. - The emphasis on biomarkers, nanocarriers and stealth liposomes points to a market moving from basic formulation innovation toward more personalized treatment design. - A cited National Library of Medicine estimate says U.S. prescription drug spending is expected to rise 10.0% to 12.0% in 2024, underscoring broader demand for advanced drug-delivery systems.

What's next: - The report expects continued momentum from clinical research, biomarker-guided therapies and combination treatment strategies. - Asia-Pacific’s faster growth could reshape regional competition as more cancer treatment capacity and drug-delivery innovation move into the region. - The Business Research Company is also promoting updated 2026 report features, including TAM analysis, company scoring tools and dashboards.

The bottom line: - Liposomal chemotherapy is moving from a niche delivery approach toward a faster-growing segment of oncology, with demand driven by safer, more targeted cancer treatment.